Please use this identifier to cite or link to this item:
Title: Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
Authors: Syn N.L.
Lim P.L.
Kong L.R.
Wang L. 
Wong A.L.-A. 
Lim C.M. 
Loh T.K.S. 
Siemeister G.
Goh B.C. 
Hsieh W.-S. 
Issue Date: 2018
Publisher: Springer Nature
Citation: Syn N.L., Lim P.L., Kong L.R., Wang L., Wong A.L.-A., Lim C.M., Loh T.K.S., Siemeister G., Goh B.C., Hsieh W.-S. (2018). Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduction and Targeted Therapy 3 (1) : 9. ScholarBank@NUS Repository.
Abstract: In addition to their canonical roles in regulating cell cycle transition and transcription, cyclin-dependent kinases (CDKs) have been shown to coordinate DNA damage response pathways, suggesting a rational pairing of CDK inhibitors with genotoxic chemotherapeutic agents in the treatment of human malignancies. Here, we report that roniciclib (BAY1000394), a potent pan-CDK inhibitor, displays promising anti-neoplastic activity as a single agent and potentiates cisplatin lethality in preclinical nasopharyngeal carcinoma (NPC) models. Proliferation of the NPC cell lines HONE-1, CNE-2, C666-1, and HK-1 was effectively curbed by roniciclib treatment, with IC50 values between 11 and 38 nmol/L. These anticancer effects were mediated by pleiotropic mechanisms consistent with successful blockade of cell cycle CDKs 1, 2, 3, and 4 and transcriptional CDKs 7 and 9, ultimately resulting in arrest at G1/S and G2/M, downregulation of the transcriptional apparatus, and repression of anti-apoptotic proteins. Considerably enhanced tumor cell apoptosis was achieved following combined treatment with 10 nmol/L roniciclib and 2.0 ?mol/L cisplatin; this combination therapy achieved a response over 250% greater than either drug alone. Although roniciclib chemosensitized NPC cells to cisplatin, it did not sensitize untransformed (NP69) cells. The administration of 0.5 mg/kg roniciclib to BALB/c xenograft mice was well tolerated and effectively restrained tumor growth comparable to treatment with 6 mg/kg cisplatin, whereas combining these two agents produced far greater tumor suppression than either of the monotherapies. In summary, these data demonstrate that roniciclib has strong anti-NPC activity and synergizes with cisplatin chemotherapy at clinically relevant doses, thus justifying further evaluation of this combinatorial approach in clinical settings. © 2018, The Author(s).
Source Title: Signal Transduction and Targeted Therapy
ISSN: 20959907
DOI: 10.1038/s41392-018-0010-0
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
s41392-018-0010-0.pdf3.89 MBAdobe PDF




checked on Oct 20, 2019

Page view(s)

checked on Oct 17, 2019


checked on Oct 17, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.